Cargando…
Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico
BACKGROUND. NVX-CoV2373, an adjuvanted, recombinant SARS-CoV-2 spike (rS) protein vaccine, consistently demonstrated protective efficacy against COVID-19 in clinical trials and has received regulatory authorizations or approvals worldwide. METHODS. PREVENT-19 (NCT04611802) is a phase 3, randomized,...
Autores principales: | Áñez, Germán, Kotloff, Karen L., Gay, Cynthia L., Nelson, Joy, Dunbar, Haoua, Cloney-Clark, Shane, McGarry, Alice, Woo, Wayne, Cho, Iksung, Plested, Joyce S., Glenn, Gregory M., Dunkle, Lisa M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197803/ https://www.ncbi.nlm.nih.gov/pubmed/37214968 http://dx.doi.org/10.1101/2023.05.08.23289670 |
Ejemplares similares
-
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents
por: Áñez, Germán, et al.
Publicado: (2023) -
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023) -
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023) -
NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial
por: Marchese, Anthony M., et al.
Publicado: (2023) -
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
por: Dunkle, Lisa M., et al.
Publicado: (2021)